Trump's Medicare Obesity Drug Plan 'BALANCE' Stalls as Insurers Balk at Financial Risk

The Trump administration's high-profile plan to provide seniors with cheap weight-loss drugs through Medicare is hitting a major roadblock. The initiative, which hinges on a voluntary pilot program, is at risk of unraveling as key health insurers signal deep reluctance to participate, fearing the arrangement will be a financial drain.

The program, named BALANCE, was crafted last year through a deal with pharmaceutical giants Eli Lilly and Novo Nordisk. In exchange for lowering the price of their popular obesity drugs to $245 per month for Medicare and Medicaid, the administration proposed waiving a long-standing prohibition on Medicare coverage for weight-loss medications. The goal was to test whether covering these drugs would save the government money or improve health outcomes without increasing costs. However, the model requires Medicare beneficiaries to pay only $50 monthly, leaving insurers to absorb the remaining $195 per patient—a structure that has sparked significant resistance from the very companies needed to make the pilot work.

This insurer pushback creates a critical snag for a policy the administration has touted as a win for seniors and a test of fiscal responsibility. The stalemate puts the entire pilot in jeopardy, highlighting the complex financial tensions between government cost-control ambitions, pharmaceutical pricing, and insurer profitability. Without insurer participation, the plan to expand access to drugs like those from Lilly and Novo Nordisk cannot move forward, leaving a key campaign promise in limbo and exposing the fragile economics of integrating expensive new drug classes into public health programs.